嗜酸乳杆菌、长双歧杆菌上清液对HCT116、SW480细胞增殖的影响

中国药物评价 ›› 2022, Vol. 39 ›› Issue (5): 414-417.

嗜酸乳杆菌、长双歧杆菌上清液对HCT116、SW480细胞增殖的影响

周轶平1，任宝军2，农晓翠3，毛勇1，陈铭然1，罗敏1，杨焕芝2*

1.昆明医科大学，云南昆明 650500； 2.昆明市第一人民医院，云南昆明 650034； 3.昆明学院，云南昆明 650214

收稿日期:2022-08-24 修回日期:2022-08-29 出版日期:2022-10-28 发布日期:2022-10-28
基金资助:
昆明市卫健委局级卫生科研项目（2020-13-01-113）；昆明市卫生科技人才培养项目[项目编号：2020-SW（省）-13]

Effects of Supernatant of Lactobacillus Acidophilus and Bifidobacterium Longum on Proliferation of HCT116 and SW480 Cells

1.Kunming Medical University， Yunnan Kunming 650500，China；
2.Kunming Municipal First People′s Hospital， Yunnan Kunming 650034，China；
3.Kunming University， Yunnan Kunming 650214， China

Received:2022-08-24 Revised:2022-08-29 Online:2022-10-28 Published:2022-10-28
Contact: yang huanzhi E-mail:yanghuanzhi1024@163.com

摘要/Abstract

摘要： 目的：研究嗜酸乳杆菌（ATCC 4356)与长双歧杆菌（ATCC 15707)上清液对HCT116、SW480人结肠癌细胞增殖作用的影响。方法：体外培养HCT116、SW480、嗜酸乳杆菌和长双歧杆菌，分别提取嗜酸乳杆菌和长双歧杆菌的上清液。通过MTT法分析嗜酸乳杆菌和长双歧杆菌不同组分对人结肠癌细胞增殖的影响。结果：嗜酸乳杆菌上清液对SW480细胞抑制作用弱于MRS培养基（F=7.24，P=0.043 3）；长双歧杆菌上清液与BHI培养基对SW480细胞抑制作用的差异无统计学意义（F=1.81，P=0.236 6），而不同浓度之间细胞抑制率的差异有统计学意义（F=18.07，P=0.003 2）；嗜酸乳杆菌上清液对HCT116细胞抑制作用强于MRS培养基（F=10.33，P=0.023 6），而不同浓度之间细胞抑制率的差异无统计学意义（F=3.51，P=0.097 3）；BHI培养基对HCT116细胞促增殖作用强于长双歧杆菌上清液（F=41.12，P=0.001 4）。结论：嗜酸乳杆菌上清液在一定的浓度范围内对HCT116细胞增殖具有抑制作用，对SW480细胞无抑制作用。长双歧杆菌上清液对SW480、HCT116细胞均无抑制作用。

关键词: font-size:medium, ">嗜酸乳杆菌；长双歧杆菌；细胞增殖；人结肠癌细胞

Abstract: Objective：To study the effects of supernatant of Lactobacillus acidophilus (ATCC 4356) and Bifidobacteria longifolia (ATCC 15707) on the proliferation of human colon cancer cells HCT116 and SW480. Methods： HCT116， SW480， Lactobacillus acidophilus and bifidobacterium longum were cultured in vitro. The supernatants of Lactobacillus acidophilus and bifidobacterium longum were extracted respectively. The effects of different components of Lactobacillus acidophilus and Bifidobacterium longum on proliferation of human colon cancer cells were analyzed by MTT assay. Results： The inhibitory effect of Lactobacillus acidophilus supernatant on SW480 cells was weaker than that of MRS medium (F=7.24， P=0.043 3). There was no significant difference in the inhibitory effect of bifidobacterium longeum supernatant and BHI medium on SW480 cells (F=1.81， P=0.236 6)， while there was significant difference in the inhibitory rate of SW480 cells between different concentrations (F=18.07， P=0.003 2). The inhibitory effect of Lactobacillus acidophilus supernatant on HCT116 cells was stronger than that of MRS medium (F=10.33， P=0.023 6)， but there was no significant difference in cell inhibition rate between different concentrations (F=3.51， P=0.097 3).The effect of BHI medium on HCT116 cell proliferation was stronger than that of bifidobacterium longeum supernatant (F=41.12，P=0.001 4). Conclusion： The supernatant of Lactobacillus acidophilus can inhibit the proliferation of HCT116 cells in a certain concentration range， but has no inhibitory effect on SW480 cells. The supernatant of bifidobacterium longum has no inhibitory effect on SW480 and HCT116 cells.

Key words: font-size:medium, ">Lactobacillus acidophilus； Bifidobacterium longum； Cell proliferation； Human colon cancer cell

中图分类号:

周轶平, 任宝军, 农晓翠, 毛勇, 陈铭然, 罗敏, 杨焕芝. 嗜酸乳杆菌、长双歧杆菌上清液对HCT116、SW480细胞增殖的影响[J]. 中国药物评价, 2022, 39(5): 414-417.

ZHOU Yi-ping, REN Bao-jun, NONG Xiao-cui, MAO Yong, CHEN Ming-ran, LUO Min, YANG Huan-zhi. Effects of Supernatant of Lactobacillus Acidophilus and Bifidobacterium Longum on Proliferation of HCT116 and SW480 Cells[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2022, 39(5): 414-417.

参考文献

[1]Sung H, Ferlay J, Siegel R L, et al.Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36Cancers in 185 Countries[J].CA Cancer J Clin, 2021, 71(3):209-249 [2]Cao W, Chen H D, Yu Y W, et al.Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chin Med J, 2021, 134(7):783-791 [3]Khan S, Moore RJ, Stanley D, et al.The gut microbiota of laying hens and its manipulation with prebiotics and probiotics to enhance gut health and food safety[J].Applied and Environmental Microbiology, 2020, 86(13):1-18 [4]Bhalla P, Rengaswamy R, Karunagaran D, et al.Metabolic modeling of host–microbe interactions for therapeutics in colorectal cancer[J].NPJ Syst Biol Appl, 2022, 8(1):1-10 [5]Heydari Z, Rahaie M, Alizadeh AM, et al.Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b,26b,18a and 155,and Their Involving Genes in Mice Colon Cancer[J].Probiotics and antimicrobial proteins, 2019, 11(4):1155-1162 [6]杨焕芝, 周轶平, 翁稚颖, 等.旱生香茶菜素对细胞抗肿瘤活性[J].医药导报, 2017, 36(4):379-384 [7]Nami Y, Abdullah N, Haghshenas B, et al.Probiotic potential and biotherapeutic effects ofnewly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells［J. Anaerobe, 2014, 28:29?36.[J].Anaerobe, 2014, 28(1):29-36 [8]Yue YX, [1]Sung H， Ferlay J， Siegel R L， et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36Cancers in 185 Countries[J]. CA Cancer J Clin， 2021， 71(3)： 209-249.
     [2]Cao W， Chen HD， Yu YW， et al. Changing profiles of cancer burden worldwide and in China： a secondary analysis of the global cancer statistics 2020[J]. Chin Med J， 2021， 134(7)： 783-791.
     [3]黄灿，程晟，沈素.微生态制剂及其临床应用研究进展[J].中国医院用药评价与分析，2015，15(4)：440-442.
     [4]Bhalla P， Rengaswamy R， Karunagaran D， et al. Metabolic modeling of host-microbe interactions for therapeutics in colorectal cancer [J]. NPJ Syst Biol Appl，2022，8(1)：1.
     [5]Heydari Z，Rahaie M，Alizadeh AM， et al. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum Probiotics on the Expression of MicroRNAs 135b， 26b， 18a and 155， and Their Involving Genes in Mice Colon Cancer[J]. Probiotics and Antimicrobial Proteins，2019，11(4)：1155-1162.
     [6]杨焕芝，周轶平，翁稚颖，等.旱生香茶菜素G对S180细胞抗肿瘤活性[J].医药导报，2017，36(4)：379-384.
     [7]Xu HY， Hiraishi K， Kurahara LH，et al. Inhibitory effects of breast milk-derived Lactobacillus rhamnosus Probio-M9 on colitis-associated carcinogenesis by restoration of the gut microbiota in a mouse model[J]. Nutrients，2021，13(4)：1143.
     [8]刘华清，林蕤，陈永，等.特异乳酸菌对环磷酰胺抗人大肠癌HCT116细胞作用的影响[J].中国药房，2016，27(1)：47-49.
     [9]Nami Y， Abdullah N， Haghshenas B， et al. Probiotic potential and biotherapeutic effects ofnewly isolated vaginal Lactobacillus acidophilus 36YL strain on cancer cells[J]. Anaerobe， 2014， 28：29-36.
     [10]Yue YX，Wang S，Shi Jl， et al. Effects of Lactobacillus acidophilus KLDS1.0901 on Proliferation and Apoptosis of Colon Cancer Cells[J].Front Microbiol，2022，12：788040.
     [11]Behzadi R，Hormati A，Eivaziatashbeik K， et al. Evaluation of Anti-Tumor Potential of Lactobacillus acidophilus ATCC4356 Culture Supernatants in MCF-7 Breast Cancer[J]. Anticancer Agents Med Chem，2021，21(14)：1861-1870.
     [12]Agah S，Alizadeh AM，Mosavi M， et al. More Protection of Lactobacillus acidophilus Than Bifidobacterium bifidum Probiotics on Azoxymethane-Induced Mouse Colon Cancer[J]. Probiotics and antimicrobial proteins，2019，11(3)：857-864.
     [13]Ranji P， Agah S， Heydari Z， et al. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the serum biochemical parameters， and the vitamin D and leptin receptor genes on mice colon cancer[J]. Iranian Journal of Basic Medical Sciences，2019， 22(6)：631-636.

[1]	李川, 杨军令, 程晨, 贾伟伟. 中药新药的药代研究[J]. 中国药物评价, 2023, 40(6): 457-459.
[2]	叶潇, 郑爽#, 林超, 黄舒佳, 王宇, 于敏, 刘颖. 生物分析方法验证及生物样品分析各指导原则间的比较[J]. 中国药物评价, 2023, 40(6): 470-479.
[3]	李丽, 刘婉如, 张征, 江志杰, 李宁. 逐瘀通脉胶囊对大鼠急性局灶性脑缺血再灌注损伤的影响[J]. 中国药物评价, 2023, 40(6): 502-505.
[4]	颜若曦. 《PIC/S生物技术检查备忘录》分析与探讨[J]. 中国药物评价, 2023, 40(6): 537-540.
[5]	甘加明, 邹瑜, 黄丹, 陈冬华, 严全鸿. 基于流池法的氨糖美辛肠溶片体外溶出行为研究[J]. 中国药物评价, 2023, 40(6): 480-484.
[6]	徐桂连, 董斌, 韩春晖, 郝爱鱼. 磷酸苯丙哌林多晶型制备、表征及平衡溶解度研究[J]. 中国药物评价, 2023, 40(6): 489-493.
[7]	代琪, 李康曦, 叶俏波, 文永盛, 许莉, 李及. 僵蚕化学成分、药理作用及毒理学研究进展[J]. 中国药物评价, 2023, 40(5): 402-408.
[8]	赵磊, 杨铭, 王皓, 马彧, 马金刚, 姜大成, 王路宏, 昝珂. 沙棘不同采收期与不同干燥过程真菌毒素的考察及其风险评估[J]. 中国药物评价, 2023, 40(5): 377-383.
[9]	洪淑华, 林琪珊, 柴将红, 潘红炬. 佐匹克隆有关物质及其校正因子影响因素的测定研究[J]. 中国药物评价, 2023, 40(5): 384-388.
[10]	李悦忱, 崔韶婧, 赵月然. 高效液相色谱-柱后光化学衍生法测定活血止痛胶囊中黄曲霉毒素的含量[J]. 中国药物评价, 2023, 40(5): 390-395.
[11]	田洁, 郝爱鱼, 鹿麟, 邹翩, 董斌. 几种药物配伍对常见塑料包装输液产品中不溶性微粒的影响研究[J]. 中国药物评价, 2023, 40(5): 396-401.
[12]	杨艳青, 陈春梅, 陈伟, 吴瑞, 王学昌, 段莲. 信迪利单抗一线治疗晚期非小细胞肺癌的快速卫生技术评估[J]. 中国药物评价, 2023, 40(5): 409-415.
[13]	江依帆, 陈丽萍, 张若钰, 巫培豪, 邱嘉珉, 宣建伟, 毕惠嫦. 抑酸药物的临床综合评价指标体系构建[J]. 中国药物评价, 2023, 40(5): 416-421.
[14]	华敏凡, 宋沧桑, 李兴德, 陆维, 毛盼盼, 王国徽. 服药依从性预测模型临床应用研究进展[J]. 中国药物评价, 2023, 40(5): 422-425.
[15]	黄波, 曹晓明. 等渗与低渗造影剂对老年肾功能损伤患者行冠脉造影术的安全性临床观察[J]. 中国药物评价, 2023, 40(5): 426-429.